Drug Trial Radar · NCT05296629
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
Last checked: Nov 20, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Mar 14, 2022
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Journey Medical CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Dr. Reddy's Laboratories Limited, India
- First posted
- Mar 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks.
Conditions
- Papulopustular Rosacea
Interventions
DFD-29Drug
DFD-29 (40 mg) extended release capsules
DoxycyclineDrug
Doxycycline 40 mg capsules
PlaceboDrug
Placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.Time frame: Baseline to Week 16.
- Change in Total Inflammatory Lesion Count Compared to Placebo.Time frame: Baseline to Week 16.
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site 05
Rogers, Arkansas
Clinical Trial Site 10
Cerritos, California
Clinical Trial Site 03
Fremont, California
Clinical Trial Site 25
San Diego, California
Clinical Trial Site 29
San Diego, California
Clinical Trial Site 11
Clearwater, Florida
Clinical Trial Site 08
Coral Gables, Florida
Clinical Trial Site 22
Coral Gables, Florida
Clinical Trial Site 02
Indianapolis, Indiana
Clinical Trial Site 27
Overland Park, Kansas
Clinical Trial Site 09
Brighton, Massachusetts
Clinical Trial Site 18
Ann Arbor, Michigan
Clinical Trial Site 28
Warren, Michigan
Clinical Trial Site 21
New Brighton, Minnesota
Clinical Trial Site 15
Las Vegas, Nevada
Clinical Trial Site 24
New York, New York
Clinical Trial Site 17
High Point, North Carolina
Clinical Trial Site 04
Wilmington, North Carolina
Clinical Trial Site 06
Beachwood, Ohio
Clinical Trial Site 01
Sugarloaf, Pennsylvania
Clinical Trial Site 19
East Greenwich, Rhode Island
Clinical Trial Site 23
Nashville, Tennessee
Clinical Trial Site 20
College Station, Texas
Clinical Trial Site 13
Houston, Texas
Clinical Trial Site 07
Plano, Texas
Clinical Trial Site 26
San Antonio, Texas
Clinical Trial Site 12
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.